Authoritative Definition and Comprehensive Review of ADHD

Disclaimer: This article presents aggregated research findings. It is not a medical paper, cannot substitute for a physician, and should not be used as diagnostic evidence. The reasoning and conclusions in this article involved AI-assisted generation, have not undergone peer review or independent verification, and may contain errors.

TL;DR (Three Core Conclusions)

ADHD is a neurodevelopmental disorder characterized by developmentally inappropriate inattention, hyperactivity, and impulsivity as core symptoms. Both DSM-5-TR (APA, 2022) and ICD-11 (WHO, 2022, code 6A05) require symptom onset before age 12, cross-situational presence (≥2 settings), and clear functional impairment; DSM-5-TR requires children (≤16 years) to meet ≥6 of 9 inattention or 9 hyperactivity-impulsivity symptoms, and adults aged 17 and above to meet ≥5 of each, persisting for ≥6 months.
ADHD is not a "childhood-only" disorder: the pooled childhood prevalence is approximately 5.29% (Polanczyk et al., 2007, Am J Psychiatry), and approximately 65% persist functionally into adulthood (Faraone, Biederman & Mick, 2006, Psychol Med); global adult symptomatic ADHD is approximately 6.76%, and persistent ADHD approximately 2.58% (Song et al., 2021, J Glob Health). Twin-study heritability of ADHD is approximately 74% (Faraone & Larsson, 2019, Mol Psychiatry), with 27 confirmed GWAS loci (Demontis et al., 2023, Nat Genet).
Core clinical takeaway: ADHD is not laziness, not parenting failure, not simply "inability to focus" — it is a disorder of executive function and self-regulation caused by catecholamine (dopamine/norepinephrine) dysregulation in the prefrontal cortex (PFC), typically accompanied by emotional dysregulation (Barkley's DESR model; Shaw et al., 2014, Am J Psychiatry); stimulants (methylphenidate, amphetamines) are first-line treatment, and the network meta-analysis by Cortese et al. (2018, Lancet Psychiatry 5:727–738) recommends methylphenidate as the first choice for children and adolescents, and amphetamines for adults.

Key Findings

1. Official Definitions

DSM-5-TR (APA, 2022) classifies ADHD under "Neurodevelopmental Disorders," defined as a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. Diagnostic requirements:

Symptom threshold: Of 9 inattention symptoms, children (≤16 years) require ≥6, age 17 and above require ≥5; the same applies for 9 hyperactivity-impulsivity symptoms; persisting ≥6 months and inconsistent with developmental level.
Three presentations (replacing DSM-IV "subtypes"):
1. Predominantly Inattentive
2. Predominantly Hyperactive-Impulsive
3. Combined
Age of onset: Several symptoms must be present before age 12 (DSM-IV required age 7).
Cross-situational: Symptoms must be present in ≥2 settings (e.g., home, school, work, social).
Functional impairment: Symptoms must clearly interfere with or reduce the quality of social, academic, or occupational functioning.
Exclusion: Cannot be better explained by schizophrenia or other psychotic disorders.

ICD-11 (WHO, 2022): code 6A05, also classified under "Neurodevelopmental Disorders." Key differences from DSM-5-TR:

ICD-11 adopts a more descriptive, prototype-based approach rather than DSM's item-by-item symptom counting; it requires a "persistent pattern (at least 6 months)" with severity "beyond the range of normal variation for age and intellectual level."
ICD-11 also includes three presentations (6A05.0/0.1/0.2), plus residual categories 6A05.Y (other specified) and 6A05.Z (unspecified).
ICD-11 language more explicitly provides anchoring for differential diagnosis in individuals with lower intellectual ability; it also accepts onset age as "typically in early to middle childhood, but some individuals may not come to clinical attention until a later stage" — slightly more flexible than DSM-5-TR.

Major changes from DSM-IV to DSM-5/DSM-5-TR (APA, "Highlights of Changes from DSM-IV-TR to DSM-5"):

Added cross-age (especially adult) symptom examples
Strengthened cross-situational requirement to "several symptoms in each setting"
Onset age raised from 7 to 12 — based on Polanczyk et al. (2010) prospective study of 2,232 British children, this change increased cumulative ADHD prevalence before age 12 by only 0.1 percentage points, but significantly improved retrospective identification of adult cases
"Subtypes" renamed "presentations," acknowledging that presentation can change across life stages
Co-occurrence with autism spectrum disorder now permitted (removing DSM-IV exclusion)
Adult (≥17 years) symptom threshold lowered from 6 to 5 — based on evidence of adult functional impairment

DSM-5-TR (2022) made no substantive changes to core ADHD diagnostic criteria; updates primarily addressed epidemiological descriptions and discussion of cultural and racial disparities (Koutsoklenis & Honkasilta, 2023, Frontiers in Psychiatry 13:1064141).

2. Core Features and Phenomenology

Three core symptom dimensions:

Inattention: difficulty sustaining attention, easy distractibility, poor organization, forgetfulness, avoidance of tasks requiring sustained mental effort, frequently losing things
Hyperactivity: fidgeting, excessive running or climbing, talking excessively, appearing "driven by a motor"
Impulsivity: blurting out answers, difficulty waiting, interrupting others, acting without thinking

Executive function deficit: Barkley's model (1997, Psychol Bull 121:65–94) reconceptualized ADHD as a "disorder of self-regulation," involving impairment in four executive functions — working memory, internalized speech, behavioral inhibition, self-regulation of emotion/motivation, and reconstitution. Neurobiologically, executive function deficits map to norepinephrine and dopamine signaling dysregulation in the dorsolateral prefrontal cortex (dlPFC) (Arnsten, 2011, Biol Psychiatry 69:e89–e99).

Emotional dysregulation and Barkley's DESR model: Barkley (2010, J ADHD Relat Disord 1:5–37; 2015 in ADHD: A Handbook for Diagnosis and Treatment, 4th ed., Guilford) proposed "Deficient Emotional Self-Regulation" (DESR) as a core component of ADHD, rather than a comorbid feature. Shaw, Stringaris, Nigg & Leibenluft (2014, American Journal of Psychiatry 171:276–293) provided a systematic review supporting it as a core feature of ADHD. Graziano & Garcia (2016) meta-analyzed 77 studies (N=32,044) showing ADHD patients are impaired in emotion recognition and understanding, emotional reactivity/lability, and empathy/callous-unemotional traits.

ADHD inattention vs normal distraction:

Persistence (chronic vs situational)
Pervasiveness (pervasive vs context-bound)
Early childhood onset (developmental onset)
Significant functional impairment (impairment)
Unrelated to willpower or motivation — the "hyperfocus" paradox: individuals can display excessive concentration on high-interest or high-stimulation tasks and have difficulty disengaging; the problem lies in top-down regulation of attention, not quantity of attention

3. Epidemiology

Child and adolescent prevalence: Polanczyk, de Lima, Horta, Biederman & Rohde (2007, Am J Psychiatry 164:942–948) systematic review and meta-regression analysis yielded a global pooled child/adolescent ADHD/HD prevalence of 5.29%; Polanczyk, Willcutt, Salum, Kieling & Rohde (2014, Int J Epidemiol 43:434–442) updated analysis showed the true prevalence has been stable at approximately 5.3% over three decades, with variability mainly explained by methodological differences rather than true increases in prevalence.
Adult prevalence:
- Fayyad et al. (2017, ADHD Atten Defic Hyperact Disord 9:47–65, WHO World Mental Health Surveys, 20 studies, 13 countries, >26,000 individuals) estimated adult DSM-IV ADHD prevalence at 2.8%.
- Song, Zha, Yang, Zhang, Li & Rudan (2021, J Glob Health 11:04009) adjusted for 2020 global population structure and estimated persistent adult ADHD at 2.58% (95% CI 1.51–4.45) and symptomatic adult ADHD at 6.76% (95% CI 4.31–10.61); global 2020 estimates of 139.8 million persistent adult ADHD cases (95% CI 81.64–240.99 million) and 366.3 million symptomatic adult ADHD cases (95% CI 233.75–574.85 million); the 18–24 age group had the highest proportion (persistent 5.05%, symptomatic 8.99%), declining with age to 0.77% (persistent) above age 60.
Sex ratio: Clinical diagnosis in childhood male:female approximately 4:1, community/population samples approximately 2:1; in adulthood approaching 1:1 (Willcutt, 2012, Neurotherapeutics; Hinshaw et al., 2022, J Child Psychol Psychiatry "Annual Research Review").
Historical underdiagnosis of females: Hinshaw, Nguyen, O'Grady & Rosenthal (2022) emphasized that females more often present with inattentive and internalizing symptoms, with less disruptive behavior, leading to lower teacher and parent referral rates, delayed clinical identification, and frequent misdiagnosis as anxiety or depression. Mowlem et al. (2019, Swedish study of 51,527 children) confirmed that girls displaying ADHD symptoms are more likely to remain undiagnosed than boys.
Age of onset: Typically in early to middle childhood (both DSM-5-TR and ICD-11 require before age 12).
Persistence into adulthood: Faraone, Biederman & Mick (2006, Psychol Med 36:159–165) meta-analysis showed: using full DSM-IV criteria, syndromatic persistence rate is only approximately 15% (at age 25); but when including "partial remission" and functional persistence, approximately 65% still have significant symptoms or impairment at age 25.

4. Differential Diagnosis

ADHD vs Bipolar Disorder (BD) (Marangoni, De Chiara & Faedda, 2015, J Psychiatr Pract; Asherson et al.):

Dimension	ADHD	Bipolar Disorder
Course	Chronic, persistent	Episodic, cyclical
Onset	Childhood (<12 years)	Typically late adolescence or early adulthood
Mood symptoms	Absent (may have emotional dysregulation, but not mood episodes)	Manic/hypomanic episodes required
Subjective cognitive experience	Subjective sense of reduced cognitive ability	Subjective sense of enhanced cognitive ability during mania
Psychotic symptoms	None	May be present

Comorbidity rate: Schiweck et al. (2021, Neuroscience & Biobehavioral Reviews, 71 studies, N=646,766, 18-country meta-analysis) showed approximately 17.11% (95% CI 13.05–21.59%) of BD patients have comorbid ADHD, and 7.95% (95% CI 5.31–11.06%) of ADHD patients have comorbid BD — substantially higher than chance expectation, suggesting genetic sharing (confirmed by Demontis et al. 2019 PRS study).

ADHD vs Borderline Personality Disorder (BPD) (Ditrich et al., 2021, Borderline Personal Disord Emot Dysregul):

Commonalities: impulsivity, emotional dysregulation, interpersonal instability
Key differences:
- BPD impulsivity is stress-dependent, with identity disturbance, emptiness, self-harm, fear of abandonment; ADHD impulsivity is motor impulsivity, without identity disturbance
- Neuroimaging: BPD primarily shows abnormalities in prefrontal-limbic systems (PFC + limbic); ADHD in caudate and frontostriatal circuits (Pinheiro et al., 2024, J Clin Med 13:6906)
- Attention deficits (especially in non-stressful contexts) point toward ADHD rather than BPD
- Onset: ADHD in childhood; BPD typically late adolescence/early adulthood
When comorbid, symptoms of both overlap and mutually worsen, requiring combined treatment (medication + dialectical behavior therapy)

ADHD vs Anxiety Disorders: Anxiety-driven "distraction" is driven by internal rumination/worry, is typically situational (e.g., exams, social situations), and is accompanied by autonomic symptoms; ADHD attention deficit is baseline, cross-situational, and often manifests as "inability to persist with boring tasks but ability to focus on interesting tasks." Kessler et al. (2006, Am J Psychiatry, NCS-R) found 47% of adults with ADHD have comorbid anxiety disorder — comorbidity rather than mutual exclusion is the norm.

ADHD vs Autism Spectrum Disorder (ASD): The core features of ASD are social communication deficits and restricted, repetitive behaviors; the core features of ADHD are attention/inhibitory control deficits. However, since DSM-5, comorbidity is permitted, and the literature shows approximately 50–70% of individuals with ASD have comorbid ADHD (Antshel & Russo, 2019 review).

ADHD vs Normal Developmental Variation: Symptoms must exceed the normal range of variation for age and developmental level (ICD-11 states this explicitly), and must meet criteria for functional impairment and cross-situational persistence. High-energy activity in preschool-age children that does not impair learning and social functioning is typically normal variation.

5. Neurobiology

Dopamine/norepinephrine hypothesis: Arnsten (2011, Biol Psychiatry 69:e89–e99 "Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks"; Arnsten & Pliszka, 2011, Pharmacol Biochem Behav) demonstrated that the dorsolateral prefrontal cortex (dlPFC) is extremely sensitive to NE and DA levels — NE enhances PFC network connectivity and sustained working memory firing through postsynaptic α2A-adrenergic receptors, while DA modulates through D1 receptors following an "inverted-U" curve. PFC hypofunction in ADHD is thought to reflect catecholamine signaling dysregulation. All current ADHD medications (stimulants, atomoxetine, guanfacine) act on this pathway.

Structural brain differences — ENIGMA Consortium: Hoogman et al. (2017, Lancet Psychiatry 4:310–319) studied 2,246 ADHD patients and 1,934 controls across 36 countries (the largest ADHD neuroimaging meta-analysis in history) and found the ADHD group had significantly smaller amygdala (d=−0.19), nucleus accumbens (d=−0.15), caudate (d=−0.11), hippocampus (d=−0.11), putamen (d=−0.14), and total intracranial volume (d=−0.10); effect sizes were largest in children and smallest in adults, supporting the "maturational delay" hypothesis (Shaw et al., 2007, PNAS 104:19649). Hoogman et al. (2019, Am J Psychiatry 176:531–542) cortical thickness analysis showed thinning in frontal, cingulate, and temporal cortex. Although statistically significant, these effects have small effect sizes and cannot be used for individual diagnosis.

Genetics:

Heritability ~74%: Faraone & Larsson (2019, Mol Psychiatry 24:562–575) synthesized 37 twin studies yielding a mean heritability of 74%; Danish population registry estimates based on clinical diagnosis reached 88%.
GWAS: Demontis et al. (2019, Nat Genet 51:63–75) first identified 12 genome-wide significant loci; Demontis et al. (2023, Nat Genet 55:198–208) expanded to 27 loci in 38,691 ADHD cases and 186,843 controls, fine-mapping 76 candidate risk genes enriched for genes expressed during early brain development (especially frontal cortex) and in midbrain dopaminergic neurons.
SNP heritability: Common variants explain 14–22% (Demontis et al., 2023); suggesting that rare variants (such as CNVs and protein-truncating variants, e.g., SORCS3 gene) also play a role — this is the "missing heritability" problem.
Polygenic risk: Significant genetic sharing with ASD, depression, bipolar disorder, educational attainment, and others.

Environmental risk factors (Faraone et al., 2021, Neurosci Biobehav Rev 128:789–818, World Federation of ADHD International Consensus Statement):

Prenatal factors:
- Maternal smoking during pregnancy is associated with ADHD — three meta-analyses involving over 3 million individuals showed >50% increase in ADHD incidence (Huang et al., 2018; Dong et al., 2018; Nilsen & Tulve, 2020); however, the association disappears after adjusting for family history, suggesting genetic confounding rather than direct causation.
- Bereavement stress (2-fold risk in boys; Li et al., 2010, Danish registry)
- Prenatal valproate exposure: 50%↑ risk (Christensen et al., 2019, Denmark, 913,000 children)
- Highest quintile of phthalate exposure: 3-fold risk (Engel et al., 2018)
- Maternal obesity: 60%↑ risk (Jenabi et al., 2019)
Perinatal: Very preterm/very low birth weight infants have approximately 3-fold increase in ADHD rates (Franz et al., 2018, meta-analysis of 12 studies, >6,000 individuals); degree of prematurity shows a dose-response relationship with ADHD (Swedish cohort of 1.2 million, Lindstrom et al., 2011).
Early life:
- Lead exposure — highest quintile of blood lead level vs lowest group: 4-fold ADHD risk (Braun et al., 2006); Nilsen & Tulve (2020) meta-analysis of 14 studies, >17,000 children, showed OR approximately 4.
- Severe early deprivation: Kennedy et al. (2016, J Child Psychol Psychiatry 57:1113–1125; Rutter team English and Romanian Adoptees study/ERA) demonstrated that >6 months of severe institutional deprivation can produce a persistent "deprivation-specific ADHD variant" lasting into adulthood (ages 22–25), even after adoption into well-functioning English families — this is one of the few circumstances where environment alone can cause ADHD.
Disproven/unrelated factors:
- Sugar intake (Farsad-Naeimi et al., 2020, 7 studies, >25,000 individuals, no association)
- Vaccines (no evidence supports any association)
- Food additives show only very small effects, detectable only through parent ratings (Nigg et al., 2012)

6. Historical Evolution

1798: Scottish physician Alexander Crichton first described "the incapacity of attending with a necessary degree of constancy to any one object."
1902: The father of British pediatrics, George Frederic Still (1868–1941), delivered three Goulstonian Lectures at the Royal College of Physicians in London on March 4, 6, and 11, titled "Some Abnormal Psychical Conditions in Children," published the same year in The Lancet 1902;1:1008–1012, 1077–1082, 1163–1168. He described 43 children of normal intelligence with severe persistent attention deficits, poor self-regulation, aggression, resistance to discipline, and "defects of moral control," noting that boys outnumbered girls — recognized as the first scientific description of ADHD.
Following the 1917–1918 encephalitis pandemic: Post-encephalitic children were observed to exhibit similar behaviors, leading to the concept of "minimal brain damage"; later renamed "minimal brain dysfunction" (MBD).
1937: Charles Bradley serendipitously discovered that Benzedrine (amphetamine) significantly improved hyperactive children's behavior — the origin of stimulant treatment.
1957: Laufer, Denhoff & Solomons named the condition "hyperkinetic impulse disorder."
1968 (DSM-II): Formally included as "Hyperkinetic Reaction of Childhood."
1980 (DSM-III): Renamed "Attention Deficit Disorder" (ADD), distinguishing "with" or "without hyperactivity" — the first time inattention was placed at the diagnostic core.
1987 (DSM-III-R): Renamed to the current "Attention-Deficit Hyperactivity Disorder (ADHD)," merged into a single type.
1994 (DSM-IV): Distinguished three subtypes (inattentive, hyperactive-impulsive, combined), onset age requirement <7 years.
2013 (DSM-5): Major changes — classified under "Neurodevelopmental Disorders" (moved from the former "Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence" category); "subtypes" renamed "presentations"; onset age changed to 12; adult threshold lowered to 5; co-occurrence with ASD permitted; cross-age examples added.
2022 (DSM-5-TR, ICD-11): DSM-5-TR made no core criteria changes to the ADHD section, primarily updating epidemiological and cultural considerations; ICD-11 (6A05) presentations fully correspond with DSM-5-TR.

7. Adult ADHD

Persistence rate: Faraone, Biederman & Mick (2006, Psychol Med 36:159–165) meta-analysis showed syndromatic persistence rate of approximately 15% (at age 25), but symptomatic/functional persistence rate of approximately 65% — meaning most childhood ADHD cases still have significant symptoms or impairment in adulthood.
Adult-specific phenomenology: Motor hyperactivity tends to internalize as "subjective restlessness" (internalized restlessness), incessant talking, or racing thoughts; inattention becomes dominant, manifesting as procrastination, organizational failure, poor time management, and deadline chaos; emotional dysregulation and impulsive decision-making (Barkley, 2010) are prominent.
Functional impairment:
- Traffic accidents: Vaa (2014, Accident Analysis & Prevention) meta-analysis of 16 studies showed driver ADHD relative risk RR=1.36 (95% CI 1.18–1.57), adjusted for driving mileage RR=1.23 (95% CI 1.04–1.46).
- Employment and income: Jangmo et al. (2021, PLOS ONE, Swedish cohort of 1.2 million compulsory education graduates, 16-year follow-up) showed ADHD patients had 17% lower mean annual income (ratio 0.83, 95% CI 0.83–0.84), 12.19 more unemployment days per year (95% CI 11.89–12.49), and disability pension risk OR=19.0.
- Increased rates of substance use disorders, relationship breakdowns, and comorbid depression/anxiety.
Controversy over "adult-onset" ADHD: Moffitt et al. (2015, Am J Psychiatry 172:967–977, Dunedin longitudinal cohort), Agnew-Blais et al. (2016, JAMA Psychiatry 73:713–720, E-Risk cohort), and Caye et al. (2016, JAMA Psychiatry 73:705–712, Brazilian Pelotas cohort) — three longitudinal studies proposed that "adult-onset ADHD" may be an independent syndrome. However, Sibley et al. (2018, Am J Psychiatry 175:140–149) reassessed MTA study data and found: after comprehensive clinical evaluation of "late-onset ADHD" cases, approximately 95% were excluded — most were explained by substance use, other psychiatric disorders, cognitive fluctuations, or assessment error. Faraone & Biederman noted these studies are affected by the "false positive paradox" and reliability asymmetry between adult self-report and parent/teacher informant ratings. Current consensus: both DSM-5-TR and ICD-11 require onset before age 12; cases truly unidentified in childhood but presenting in adulthood likely had protective factors (high IQ, supportive environment) that masked early impairment (Faraone et al., 2021 consensus statement).

8. Common Misconceptions

ADHD is not:

Not laziness or a character defect — it is prefrontal neural circuit dysfunction
Not caused by parenting failure — heritability is 74% (Faraone & Larsson, 2019); severe early deprivation can independently cause ADHD only under extreme circumstances (Romanian orphans)
Not merely "inability to focus" — the ADHD "hyperfocus" paradox: individuals can display excessive concentration on high-interest or high-stimulation tasks and have difficulty disengaging; the problem is attention regulation, not attention quantity
Not only a childhood condition — approximately 65% of adults have persistent symptoms/impairment
Not an overdiagnosed "epidemic" — Polanczyk et al. (2014) demonstrated true prevalence has been stable at approximately 5% for three decades; rising diagnosis rates reflect improved identification, not a true increase
Not caused by sugar, food additives, or electronic devices (Farsad-Naeimi et al., 2020; Nigg et al., 2012)
Not caused by vaccines — no scientific evidence whatsoever
Stimulant treatment does not lead to subsequent substance abuse — Wilens, Faraone, Biederman & Gunawardene (2003, Pediatrics 111:179–185) meta-analysis of 6 studies (including 5 prospective longitudinal) found that stimulant-treated ADHD patients had 1.9-fold lower risk of ADHD-related substance use disorders compared to untreated patients; it is in fact a protective factor

9. Evidence-Based Treatments

Cortese et al. (2018, Lancet Psychiatry 5:727–738) largest network meta-analysis (133 double-blind RCTs) conclusions:

Children and adolescents: All ADHD medications (amphetamines, methylphenidate, atomoxetine, guanfacine, clonidine) were superior to placebo; methylphenidate is the first choice for short-term treatment (balancing efficacy and tolerability).
Adults: Amphetamines, methylphenidate, bupropion, and atomoxetine were all superior to placebo (modafinil was not); amphetamines are the first choice for adults (superior to modafinil, atomoxetine, and methylphenidate in head-to-head comparisons, SMDs −0.94 to −0.29).
Tolerability: Amphetamines were less tolerable than placebo in both age groups; atomoxetine, methylphenidate, and modafinil were less tolerable than placebo in adults.

Medication classes:

Stimulants: Methylphenidate-type (methylphenidate, dexmethylphenidate) and amphetamine-type (amphetamine, dextroamphetamine, lisdexamfetamine) — inhibit DAT/NET transporters, increasing PFC catecholamine levels; first-line choice.
Non-stimulants:
- Atomoxetine (Strattera, selective NE reuptake inhibitor)
- Guanfacine ER (α2A-adrenergic receptor agonist, Intuniv)
- Clonidine ER (α2-adrenergic agonist)
- Viloxazine ER (FDA-approved 2021, Qelbree)
- Bupropion (off-label use)

Psychosocial interventions:

Children: Parent behavior training (e.g., PCIT, Triple P), classroom behavior management, organizational skills training
Adolescents/Adults: Cognitive behavioral therapy (CBT) for adult ADHD (Safren et al., 2010, JAMA), ADHD coaching, organizational/time management skills, psychoeducation
Comprehensive meta-analysis (Catala-Lopez et al., 2017) showed behavioral therapy combined with stimulants is superior to either alone

Details

Clinical Details of the "6+9+9" Symptom Items

Nine inattention items (DSM-5-TR abbreviated): (1) Careless mistakes in details; (2) Difficulty sustaining attention; (3) Appears not to listen; (4) Fails to follow through on instructions/tasks; (5) Difficulty organizing; (6) Avoids tasks requiring sustained mental effort; (7) Loses necessary items; (8) Easily distracted by external stimuli; (9) Forgetful in daily activities.

Nine hyperactivity-impulsivity items: (1) Fidgets; (2) Leaves seat at inappropriate times; (3) Runs/climbs at inappropriate times (in adults, subjective restlessness); (4) Unable to engage quietly in leisure activities; (5) "Driven by a motor"; (6) Talks excessively; (7) Blurts out answers; (8) Difficulty waiting turn; (9) Interrupts/intrudes on others.

DSM-5-TR added adult examples (e.g., "persistently daydreaming during work meetings," "unable to complete reports on time," "visibly restless during long meetings") — reflecting recognition that symptom presentation varies across age groups.

Barkley's Unified Executive Function Model

Barkley (1997, Psychol Bull 121:65–94 "Behavioral Inhibition, Sustained Attention, and Executive Functions") proposed that the fundamental deficit in ADHD is behavioral inhibition impairment, which subsequently damages four executive functions. In later work (2010, 2015), he incorporated emotional self-regulation as a core component, arguing that the DSM's omission of emotional symptoms is a major gap, especially for adult ADHD.

Clinical Implications of ENIGMA Results

Although ENIGMA structural brain differences are statistically significant, their effect sizes are small (Cohen's d approximately 0.1–0.2), far below the threshold needed for individual diagnosis — this means: (a) Neuroimaging cannot be used for individual ADHD diagnosis; (b) ADHD is a highly heterogeneous disorder at the neurobiological level; (c) Group-level differences support the neurodevelopmental hypothesis but do not support neuroimaging as a clinically applicable biomarker (Faraone et al., 2021 consensus statement explicitly makes this point).

Recommendations

For clinicians:

Strictly adhere to DSM-5-TR or ICD-11 criteria when diagnosing: All four elements — symptom count, cross-situational presence, onset before age 12, and functional impairment — are indispensable.
Must use multiple informant sources: For children, parent + teacher ratings are needed (e.g., Conners-3, SDQ, Vanderbilt); for adults, collateral informant reports (parent/partner recall) are needed to correct self-report bias — Sibley (2018) demonstrated that adult self-report alone is unreliable.
Screen for comorbidities: Depression, anxiety (comorbid in approximately 47% of adult ADHD), substance use, learning disabilities, ASD, sleep disorders, BPD/BD (BD-ADHD comorbidity approximately 17%) — comorbidity rate >50%.
Include emotional dysregulation in assessment: Although not listed in DSM formal criteria, it is clinically a key variable predicting impairment and treatment response (Barkley).
Heightened vigilance for females and ethnic minorities: Hinshaw and Mowlem studies show severe underdiagnosis of female ADHD; use gender-neutral symptom descriptions to reduce bias toward externalizing symptoms.
Late-presenting adult symptoms: Evaluate cautiously; first rule out depression, anxiety, substance use, sleep deprivation, thyroid dysfunction, and neurocognitive disorders.

Treatment decision thresholds (based on Cortese et al., 2018):

Child/adolescent ADHD with moderate impairment → First choice: methylphenidate (if no contraindications);
Adult ADHD → First choice: amphetamines or methylphenidate;
Stimulant intolerance / comorbid anxiety / substance abuse risk → Switch to atomoxetine or guanfacine ER;
Preschool children (<6 years) → First choice: parent behavior training, not medication (AAP guidelines 2019);
Co-occurring emotional dysregulation or oppositional defiant behavior → Combine with CBT or behavioral therapy.

For educators and families:

Accept that ADHD is a neurobiological reality, but treatment response is good;
Implement environmental structuring, visible schedules, external reminder systems, and task chunking;
Stimulant treatment does not lead to subsequent substance abuse; on the contrary, it reduces risk by 1.9-fold (Wilens et al., 2003) — do not refuse treatment due to this stigma.

Key thresholds for changing the approach:

If a true manic episode occurs (>4 days of elevated/irritable mood + increased goal-directed activity + decreased need for sleep) → Reassess as bipolar disorder, stabilize mood first before considering stimulants;
If identity disturbance, self-harm, and fear of abandonment dominate the clinical picture → Assess for BPD, with dialectical behavior therapy (DBT) as the primary approach;
If there is complete absence of childhood symptom evidence (parents/school records all negative) → Exercise caution in diagnosing adult ADHD; rule out other causes first.

Caveats

Scientific limitations of diagnostic criteria: DSM-5-TR and ICD-11 definitions of ADHD remain descriptive/operational, not based on clearly identified etiology. Critics such as Koutsoklenis & Honkasilta (2023, Frontiers in Psychiatry) note that current definitions still carry a "neo-Kraepelinian" reductionist character and lack biomarkers; however, DSM/ICD classification remains the best available tool for clinical practice, research, insurance, and educational services.
No biomarker can be used for individual diagnosis — including neuroimaging, quantitative EEG (QEEG), genetic testing, pupillary response, etc.; diagnosis remains clinical (Faraone et al., 2021).
Regarding adult-onset ADHD: The literature has not fully settled this question. DSM-5-TR and ICD-11 maintain onset before age 12, but in clinical practice some experts (e.g., Asherson) advocate allowing treatment trials for adults with genuine impairment when childhood records are unavailable. This remains an area of active debate.
Heterogeneity of Polanczyk's 5.29% estimate: This global prevalence figure is heavily influenced by measurement methods, informant sources, and diagnostic criteria; it should not be treated as a single authoritative number while ignoring regional and methodological differences.
Heritability 74% vs SNP heritability 14–22% "missing heritability": Common variants are far from explaining total heritability, suggesting the importance of rare variants, epigenetics, and gene-environment interactions — genetic "determinism" is an oversimplification.
Research on female ADHD remains severely insufficient: The vast majority of neuroimaging, pharmacological RCTs, and longitudinal cohorts are predominantly male; treatment guidelines for females (especially regarding menstrual cycle, pregnancy, and perimenopausal hormonal effects) are extremely limited.
Regarding "hyperfocus": Although commonly self-reported by patients and clinically observed, DSM/ICD have not included it in formal symptom descriptions; its neurobiological mechanism is still under investigation.
Causality issues with environmental risk factors: Faraone et al. (2021 consensus statement) repeatedly emphasized that most environmental "risk factors" should be considered correlates rather than causes — as the vast majority of studies cannot rule out gene-environment shared confounding (the disappearance of the maternal smoking association after adjusting for family history is the clearest example).